Quality of Life with Well-Differentiated Thyroid Cancer: Treatment Toxicities and Their Reduction

Mendoza, April; Shaffer, Brian C.; Karakla, Daniel W.; Mason, M; Elkins, D. B.; Goffman, Thomas E.

doi:10.1089/105072504322880373

Cited by 64 publications

(50 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radioactive iodine is actively accumulated in salivary gland tissue, and sialadenitis is a common sequela [157][158][159][160][161][162] along with decreased salivary secretion and xerostomia [157][158][159][161][162][163]. Salivary gland hypofunction and xerostomia following radioactive iodine treatment has, by most authors, been reported to be dependent on cumulative activity [157,158,163], while others did not find this coherence [161].…”

Section: Radioactive Iodine Treatmentmentioning

confidence: 99%

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life

Jensen

Pedersen

Vissink

et al. 2010

Support Care Cancer

379

297

View full text Add to dashboard Cite

Salivary gland hypofunction and xerostomia are induced by radiotherapy in the head and neck region depending on the cumulative radiation dose to the gland tissue. Treatment focus should be on optimized/new approaches to further reduce the dose to the parotids, and particularly submandibular and minor salivary glands, as these glands are major contributors to moistening of oral tissues. Other cancer treatments also induce salivary gland hypofunction, although to a lesser severity, and in the case of chemotherapy and immunotherapy, the adverse effect is temporary. Fields of sparse literature included pediatric cancer populations, cancer chemotherapy, radioactive iodine treatment, total body irradiation/hematopoietic stem cell transplantation, and immunotherapy.

show abstract

Section: Radioactive Iodine Treatmentmentioning

confidence: 99%

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life

Jensen

Pedersen

Vissink

et al. 2010

Support Care Cancer

379

297

View full text Add to dashboard Cite

show abstract

“…Quality of life research has primarily focused on the physical side effects, and prospective, longitudinal data during the course of treatment are lacking (14)(15)(16). Neuropsychometric surveys have reported a decrement to quality of life for up to five years following treatment, on par with other cancers carrying worse prognoses (17)(18)(19).…”

Section: Introductionmentioning

confidence: 99%

Measurement and Variation in Estimation of Quality of Life Effects of Patients Undergoing Treatment for Papillary Thyroid Carcinoma

Lubitz

Gregorio

Fingeret

et al. 2017

Thyroid

View full text Add to dashboard Cite

Background: Thyroid cancer incidence is increasing. The effect of diagnosis and treatment on health-related quality of life (HRQoL) is an essential variable in the absence of a change in life span for the majority of patients. HRQoL instruments, with data useful for between-disease comparisons, are being increasingly used for health policy and outcomes evaluation. Variation exits among the instruments based on the impact of a specific disease. We assessed which of four well-validated, preference-based surveys detect changes in health and clinical intervention in patients diagnosed with papillary thyroid cancer (PTC). Methods: Four commonly used HRQoL questionnaires (Short Form-12v2Ò [SF6D], EuroQol-5D [EQ5D], and Health Utilities Index Mark 2 and 3 [HUI2, HUI3]) were administered to patients with the diagnosis of PTC at three perioperative time points during the first year of treatment. Clinicopathological and treatment course data were assessed for HRQoL impact including complications from surgery, re-operation for persistence/early recurrence, and adjuvant radioactive iodine treatment. We compared standard metrics, including ceiling effect, intraclass correlation coefficient, effect sizes, and quality-adjusted life-years between the four instruments. Results: Of 117 patients, 27% had a preoperative diagnosis of anxiety or depression, 41% had regional lymph node metastases, three had distant metastases and 49% underwent adjuvant radioactive iodine treatment. The ceiling effect (i.e., proportion with a perfect score) was greatest with EQ5D and least with SF6D. Index scores ranged from 0.77 (SF6D) to 0.90 (EQ5D). All scores declined at two weeks postoperatively and returned to pretreatment levels at six months. The SF6D was the only instrument to exceed the conventional minimally important difference between all three time points. Quality-adjusted life-years were as follows: SF6D, 0.79; EQ5D, 0.90; HUI2, 0.88; and HUI3, 0.86. Conclusions: Our results reflect the general good health of PTC patients. The effect on quality of life is primarily related to emotional and social impacts of treatment. The results support the measurement of a similar underlying construct, although variation in detecting changes in health exists between the instruments. Of the instruments assessed, the SF6D is the most responsive to treatment effects and should be utilized in future economic analyses in this patient population.

show abstract

“…In most instances, tastes returns gradually to normal or near normal levels in the first year after therapy. Since taste loss can result in weight loss, the importance of dietary counseling should be stressed [26]. Depression and anxiety are particularly worrisome and have been reported in patients with DTC and are correlated with quality of life and social support.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Quality of Life Related to I-131 Therapy in Patients with Well-Differentiated Thyroid Cancer and Emphasis in Salivary Morbidity: A Follow up Study after Treatment

Corrêa¹,

Moriguchi²,

Boldrini³

et al. 2014

ABB

View full text Add to dashboard Cite

Goal: To evaluate the impact of iodine-131 therapy received during childhood and adolescence and correlate it with the quality of life in these patients. Methods: We studied 19 patients diagnosed with cancer in childhood or adolescence who underwent thyroidectomy and supplemental therapy with I-131. We also recruited a control group of healthy subjects with the same demographic parameters. All patients were subjected to a scintigraphy examination of the salivary glands, and were also asked to complete a questionnaire in order to assess their overall quality of life. In addition, a more specific questionnaire for patients with head and neck cancer was also given to all study participants. Results: The quantitative and qualitative analyses of the salivary glands showed functional deficits with greater involvement of the parotid gland for volume, concentration and excretion. The right submandibular gland showed significant changes for volume in the patient group. The questionnaires made it possible to observe significant differences between the patient and control groups for symptoms such as thick saliva, dry mouth and speech problems. Conclusion: In spite of being very effective and widely used, iodine radionuclide therapy * Corresponding author. L. G. Corrêa et al. 410is correlated with a lower quality of life in young people.

show abstract

Quality of Life with Well-Differentiated Thyroid Cancer: Treatment Toxicities and Their Reduction

Abstract: Review of treatment-related symptoms prompted policies to reduce toxicity including amifostine pretreatment for 131I therapy and thyrotropin (synthetic TSH) use in place of iatrogenic hypothyroidism for thyroglobulin testing and scanning.

Cited by 64 publications

References 33 publications

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life

Measurement and Variation in Estimation of Quality of Life Effects of Patients Undergoing Treatment for Papillary Thyroid Carcinoma

Evaluation of Quality of Life Related to I-131 Therapy in Patients with Well-Differentiated Thyroid Cancer and Emphasis in Salivary Morbidity: A Follow up Study after Treatment

Contact Info

Product

Resources

About